Uganda has started clinical trials of a drug locally developed to treat COVID-19.
The country's President, Yoweri Museveni on Wednesday launched the trials which will involve 128 COVID-19 patients admitted at the Mulago National Referral Hospital.
The drug, a natural chemotherapeutic product developed by the Natural Chemotherapeutics Research Institute has undergone a series of vigorous scientific approvals, according to the Presidential Think Tank on Epidemics (PRESIDE).
"We are witnessing the first clinical trial of a highly scientific process to analyze and validate a natural product anticipated to have antiviral, anti-inflammatory, and immunological ability," the PRESIDE statement said.
"The clinical trial will validate the content, standardization and replication of the product after which it will be rolled out for industrial production and widespread use," the statement added.
The think tank said the drug, coded UBV-01N, will be the first Ugandan natural chemotherapeutic product to go through an international level clinical trial process.
|Disclaimer: Opinions expressed here are those of the writers and do not reflect those of Peacefmonline.com. Peacefmonline.com accepts no responsibility legal or otherwise for their accuracy of content. Please report any inappropriate content to us, and we will evaluate it as a matter of priority.|